Endothelin-1 (ET-1) is the most potent vasoconstrictor peptide known. It exerts its actions through two pharmacologically different receptors: ET A and ET B receptors. In the renal vasculature, there is a majority of ET B receptors in the efferent arteriole, while a greater amount of ET A receptors are located in the afferent arteriole. The nephron is rich in ET B receptors, especially in the thick ascending limb and collecting ducts, while containing a smaller amount of ET A receptors. High levels of circulating or renal ET-1 have been described in cardiovascular diseases such as hypertension or diabetes, diseases also associated to renal inflammation.
Introduction
Recently, ER stress has been implicated in the development of a variety of cardiovascular and renal diseases, many of which are also associated with elevated ET-1 levels. There is also extensive evidence that links increased ET-1 levels with renal immune cell infiltration and/or immune activation. This review summarizes this evidence and proposes the working hypothesis that ET-1 induces renal inflammation and/or immune activation by stimulating renal ER stress through the ET A receptor (Figure 1 ).
Endothelin and renal inflammation
ET-1 is a very potent vasoconstrictor peptide that exerts its biological actions through the activation of two G-protein coupled receptor subtypes: ET A and ET B receptors. The affinity of ET-1 for each receptor subtype has been shown to be the same (K d =0.01-0.5 nM) (4). The vasoconstrictor effects of the ET A receptor are mainly mediated by a G αq protein, while the vasodilatory effects of ET-1 through the ET B receptor are largely mediated via a G αi protein (8) .
Upregulation of the ET-1 system is implicated in many cardiovascular diseases, such as hypertension, vascular disease, pulmonary hypertension, heart failure, renal disease or diabetic nephropathy (14). Interestingly, many of these disorders have been reported to have an important inflammatory component to their development. The kidney, in particular the renal medulla, contains the highest concentration of ET-1 in the body, and progressive renal damage is described in transgenic animals overexpressing ET-1 (6). ET-1 stimulates renal hypertrophy, fibrosis and inflammation, predominantly through the activation of the ET A receptor (16, 17) .
Recently, our laboratory reported that chronic infusion of a non-pressor dose of ET-1 in Sprague-Dawley rats results in elevated circulating and renal levels of inflammatory mediators, such as ICAM-1 or MCP-1, as well as increased renal infiltration of macrophages and Tlymphocytes (13) . Interestingly, the pro-inflammatory effects exerted by ET-1 in these studies were attenuated by the administration of an ET A receptor blocker, highlighting the involvement of this receptor in the development of the ET-1-induced pro-inflammatory state. We also demonstrated that ET A receptor activation mediates renal infiltration of T cells in a hypertensive angiotensin-II infused animal model (1) . Despite a large body of evidence linking the ET-1 system with renal inflammation, the mechanism by which ET-1 leads to this inflammation remains unclear.
ER stress and renal inflammation
The endoplasmic reticulum (ER) is known to be a key cellular organelle in the modification, maturation and folding of proteins into their active conformations. The ER is also a very sensitive sensor of stress in the cell (5) . Homeostasis in the ER can be disrupted by physiological and/or pathophysiological conditions (14), leading to the accumulation of misfolded proteins in the ER, a situation known as ER stress (20). In order to maintain ER function, the cell initiates a protective mechanism known as adaptive unfolded protein response (UPR), which is directed to temporarily stop further protein transcription and translation, in an attempt to gain time for the ER to fold the accumulated misfolded proteins. Glucose-regulated protein 78 (GRP78, also known as BiP) is the molecular sensor that detects misfolded proteins within the ER, physically binding to them and initializing the 3 parallel signaling arms of the UPR by activating 3 ER membrane-associated proteins: inositol-requiring enzyme 1(IRE1), protein kinase-like ER kinase (PERK), and activating transcription factor 6 (ATF6). If the conditions triggering ER stress are too severe or prolonged in time, the cell activates the so called apoptotic UPR to remove damaged cells, which may lead to organ malfunction if too many cells are affected (5) .
Among the triggers that have been implicated in ER stress are hypoxia, ischemia and oxidative stress, all of which are linked to the development of cardiovascular and renal diseases. There is also accumulating evidence of a pathophysiological role of ER stress in acute and chronic kidney disease. ER stress is described as a contributor in glomerular diseases, such as membranous nephropathy (2), glomerulonephritis (12) , nephrotic syndrome (3), or diabetesinduced glomerular damage (10) . ER stress is also associated with tubulointerstitial damage in acute kidney injury, renal ischemia/reperfusion injury, or diabetic nephropathy (7). Substantial evidence also indicates that ER stress is interconnected with inflammatory signaling pathways.
For instance, activation of the UPR is reported to be coupled to the production of proinflammatory cytokines like MCP-1, TNF-α, IL-6 or IL-8 (18) . In addition, other studies have shown that the 3 branches of the UPR can lead to activation of the central inflammatory mediator NFκB, which induces the transcription of other inflammatory genes (21) .
ET/ET A pathway and ER stress
Given that elevated renal levels of ET-1 and renal inflammation are highlights of renal disease, our working hypothesis is that ET-1 induces renal inflammation by elevating ER stress in the kidney (Figure 1 ). The elevated ER stress levels in turn lead to the production of inflammatory mediators and renal inflammation. A recent study supports this idea by demonstrating that cultured pulmonary aortic smooth muscle cells (PASMCs) show activation of the UPR and cytokine production after exposure to ET-1 (19) . Among the upregulated pro-inflammatory cytokines were IL-6, IL-2, and CCL-5. Interestingly, these effects of ET-1 were ameliorated by treatment with an ET A receptor blocker, while treatment with an ET B receptor antagonist did not have any effect. One of the possible mechanisms by which activation of the ET A receptor could lead to renal ER stress is by generation of oxidative stress. Extensive evidence indicates that ET A receptor activation stimulates superoxide production via NADPH oxidase (15) , and that cross-talk exists between oxidative stress and ER stress (11) . Morevover, stimulation of the UPR in response to oxidative stress is an adaptive mechanism to preserve cell function and survival during renal dysfunction (9) . Modulation of renal ER stress through the ET system may be a novel therapeutic target against the development of renal disease in situations like hypertension or diabetes.
